Sponsor hub

University of Texas Southwestern Medical Center clinical trial failures

Review 100 stopped clinical trials from University of Texas Southwestern Medical Center, including disease areas, phases, and classified stop reasons.

This page groups real ClinicalTrials.gov-derived stopped trial records. The strongest added signal is the stop-reason classification: 3 of these records are likely biological failure signals, while the rest may reflect operational, strategic, regulatory, funding, enrollment, or unclear stop reasons.

Total stopped trials100
Likely biological signals3
Shown below100

Dominant stop reasons

OPERATIONAL
49
OTHER/UNKNOWN
46
EFFICACY/FUTILITY
3
REGULATORY
2

Notable sponsors

University of Texas Southwestern Medical Center
100

Related phases

Phase II
35
Phase I
26
Phase IV
18
Unknown
9
Early Phase I
6

Crawlable stopped-trial records

Open Explore

Showing up to 100 representative records from this slice. Each link opens the trial detail page with source attribution and stop-reason context.

NCT02574910: Androgen Reduction in Congenital Adrenal Hyperplasia, Phase 1

Phase I Congenital Adrenal Hyperplasia trial by University of Texas Southwestern Medical Center. Stop reason: OPERATIONAL.

The study has been affected significantly by the COVID pandemic, drug supply/drug amendment, low recruitment interest, and FDA approval of another drug with the same indication, so this study has not met its primary endpoint data requirements.

NCT03598140: Sildenafil Treatment for Mild TBI

Phase II Vascular System Injuries trial by University of Texas Southwestern Medical Center. Stop reason: OTHER/UNKNOWN.

PI, Dr. Josh Gaston, left the institution and the study has been stopped.

NCT01587261: Vitamin C for Severe Thermal Injuries

Phase II Severe Thermal Injury, Greater Than 20% TBSA trial by University of Texas Southwestern Medical Center. Stop reason: REGULATORY.

This potential study was held up at the level of the FDA as they wouldn't approve and IND for the dose of vitamin C we wanted to use.